Advertisement

Arrhythmias in Right Heart Disease

  • Stefan Bogdan
  • Radu Vătăşescu
  • Maria Dorobanţu
Chapter

Abstract

Right heart disease can be associated with increased risk for arrhythmias, both ventricular and supraventricular. Right sided arrhythmias may occur in the setting of structural disease predominantly affecting the right heart—such as cardiomyopathies (arrhythmogenic right ventricular dysplasia, cardiac sarcoidosis) and congenital heart disease (corrected tetralogy of Fallot, Ebstein’s anomaly, atrial septal defect), as well as in the absence of structural heart disease, with substrate (Mahaim fibers, Coumel type tachycardia) or without substrate (idiopathic right ventricular outflow tract ventricular tachycardia). The most common cause for right heart failure is secondary pulmonary hypertension due to left heart diseases, a setting in which the underlying left heart condition will be the main determiner for prognosis and risk of arrhythmia. Still, right heart failure secondary to pulmonary arterial hypertension is also associated with increased risk for arrhythmic events. Advanced cardiac imaging, especially cardiac MRI, as well as invasive procedures (right/left heart catherization; electrophysiological study; endomyocardial biopsy) play an important role in the differential diagnosis. Modern treatment relies on interventional techniques (implantable cardioverter defibrillator; radiofrequency ablation).

Keywords

Arrhythmogenic right ventricular dysplasia Cardiac sarcoidosis Tetralogy of Fallot Ebstein’s anomaly Ventricular tachycardia Sudden cardiac death 

References

  1. 1.
    Dalal D, James C, Devanagondi R, Tichnell C, Tucker A, Prakasa K, Spevak PJ, Bluemke DA, Abraham T, Russell SD, Calkins H, Judge DP. Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2006;48:1416–24.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Basso C, Czarnowska E, Della Barbera M, et al. Ultrastructural evidence of intercalated disc remodelling in arrhythmogenic right ventricular cardiomyopathy: an electron microscopy investigation on endomyocardial biopsies. Eur Heart J. 2006;27:1847–54.CrossRefPubMedGoogle Scholar
  3. 3.
    Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation. 1996;94:983–91.CrossRefPubMedGoogle Scholar
  4. 4.
    Te Riele ASJM, James CA, Philips B, et al. Mutation-positive arrhythmogenic right ventricular dysplasia/cardiomyopathy: the triangle of dysplasia displaced. J Cardiovasc Electrophysiol. 2013;24:1311–20.CrossRefGoogle Scholar
  5. 5.
    Hulot J-S, Jouven X, Empana J-P, Frank R, Fontaine G. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2004;110:1879–84.CrossRefPubMedGoogle Scholar
  6. 6.
    Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med. 1998;339:364–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation. 2005;112:3823–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Nava A, Bauce B, Basso C, Muriago M, Rampazzo A, Villanova C, Daliento L, Buja G, Corrado D, Danieli GA, Thiene G. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2000;36:2226–33.CrossRefPubMedGoogle Scholar
  9. 9.
    Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533–41.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Niroomand F, Carbucicchio C, Tondo C, Riva S, Fassini G, Apostolo A, Trevisi N, Bella PD. Electrophysiological characteristics and outcome in patients with idiopathic right ventricular arrhythmia compared with arrhythmogenic right ventricular dysplasia. Heart. 2002;87:41–7.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Schinkel AFL. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications. Circ Arrhythm Electrophysiol. 2013;6:562–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793–867.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Jiang H, Zhang X-L, Yang Q-L, Zhu S-H, Yu H-S, Xu B, Huang W. Catheter ablation for ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: a systematic review and meta-analysis. Acta Cardiol. 2016;71:639–49.CrossRefPubMedGoogle Scholar
  14. 14.
    Smith W. Members of CSANZ cardiovascular genetics working group: guidelines for the diagnosis and management of arrhythmogenic right ventricular cardiomyopathy. Heart Lung Circ. 2011;20:757–60.CrossRefPubMedGoogle Scholar
  15. 15.
    Wu L, Guo J, Zheng L, Chen G, Ding L, Qiao Y, Sun W, Yao Y, Zhang S. Atrial remodeling and atrial tachyarrhythmias in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 2016;118:750–3.CrossRefPubMedGoogle Scholar
  16. 16.
    Mazzanti A, Ng K, Faragli A, et al. Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of arrhythmic risk. J Am Coll Cardiol. 2016;68:2540–50.CrossRefPubMedGoogle Scholar
  17. 17.
    Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, February 1999. Am J Respir Crit Care Med. 1999;160:736–55.Google Scholar
  18. 18.
    Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther. 2016;6:50–63.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Jeudy J, Burke AP, White CS, Kramer GBG, Frazier AA. Cardiac sarcoidosis: the challenge of radiologic-pathologic correlation: from the radiologic pathology archives. Radiographics. 2015;35:657–79.CrossRefPubMedGoogle Scholar
  20. 20.
    Ueberham L, Paetsch I, Jahnke C, Klingel K, Dinov B. Right ventricular thickening and extensive late gadolinium enhancement in a patient with rare case of isolated cardiac sarcoidosis and initially negative biopsy. Eur Heart J Cardiovasc Imaging. 2017;18(12):1427–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969–77.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Yoshida Y, Morimoto S, Hiramitsu S, Tsuboi N, Hirayama H, Itoh T. Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am Heart J. 1997;134:382–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Yigla M, Badarna-Abu-Ria N, Tov N, Ravell-Weiller D, Rubin A-HE. Sarcoidosis in northern Israel; clinical characteristics of 120 patients. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG. 2002;19:220–6.Google Scholar
  24. 24.
    Iwai K, Sekiguti M, Hosoda Y, DeRemee RA, Tazelaar HD, Sharma OP, Maheshwari A, Noguchi TI. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11:26–31.PubMedGoogle Scholar
  25. 25.
    Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305–23.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Nery PB, Keren A, Healey J, Leug E, Beanlands RS, Birnie DH. Isolated cardiac sarcoidosis: establishing the diagnosis with electroanatomic mapping-guided endomyocardial biopsy. Can J Cardiol. 2013;29:1015.e1–3.CrossRefGoogle Scholar
  27. 27.
    Hulten E, Agarwal V, Cahill M, Cole G, Vita T, Parrish S, Bittencourt MS, Murthy VL, Kwong R, Di Carli MF, Blankstein R. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2016;9:e005001.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2013;34:2636–48. 2648a–2648dCrossRefPubMedGoogle Scholar
  29. 29.
    Olinde KD, O’Connell JB. Inflammatory heart disease: pathogenesis, clinical manifestations, and treatment of myocarditis. Annu Rev Med. 1994;45:481–90.CrossRefPubMedGoogle Scholar
  30. 30.
    Virk HUH, Munir MB. Isolated right ventricular myocarditis: rarely reported pathology. Case Rep Cardiol. 2015; [cited Oct 29, 2017]. Available from: https://www.hindawi.com/journals/cric/2015/790246/.
  31. 31.
    Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaitman BR. The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol. 1999;33:5–15.CrossRefPubMedGoogle Scholar
  32. 32.
    Frustaci A, Priori SG, Pieroni M, Chimenti C, Napolitano C, Rivolta I, Sanna T, Bellocci F, Russo MA. Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. Circulation. 2005;112:3680–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Zhang J, Sacher F, Hoffmayer K, et al. Cardiac electrophysiological substrate underlying the ECG phenotype and electrogram abnormalities in Brugada syndrome patients. Circulation. 2015;131:1950–9.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Kusano KF, Taniyama M, Nakamura K, et al. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. J Am Coll Cardiol. 2008;51:1169–75.CrossRefPubMedGoogle Scholar
  35. 35.
    Sroubek J, Probst V, Mazzanti A, et al. Programmed ventricular stimulation for risk stratification in the Brugada syndrome: a pooled analysis. Circulation. 2016;133:622–30.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10:1932–63.CrossRefGoogle Scholar
  37. 37.
    Loomba RS, Buelow MW, Aggarwal S, Arora RR, Kovach J, Ginde S. Arrhythmias in adults with congenital heart disease: what are risk factors for specific arrhythmias? Pacing Clin Electrophysiol PACE. 2017;40:353–61.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Baumgartner H, Bonhoeffer P, De Groot NMS, et al. ESC guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010;31:2915–57.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C, Rosenthal M, Nakazawa M, Moller JH, Gillette PC, Webb GD, Redington AN. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet Lond Engl. 2000;356:975–81.CrossRefGoogle Scholar
  40. 40.
    Nollert G, Fischlein T, Bouterwek S, Böhmer C, Klinner W, Reichart B. Long-term survival in patients with repair of tetralogy of Fallot: 36-year follow-up of 490 survivors of the first year after surgical repair. J Am Coll Cardiol. 1997;30:1374–83.CrossRefPubMedGoogle Scholar
  41. 41.
    Khairy P, Dore A, Poirier N, Marcotte F, Ibrahim R, Mongeon F-P, Mercier L-A. Risk stratification in surgically repaired tetralogy of Fallot. Expert Rev Cardiovasc Ther. 2009;7:755–62.CrossRefPubMedGoogle Scholar
  42. 42.
    Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation. 2008;117:363–70.CrossRefPubMedGoogle Scholar
  43. 43.
    Khairy P, Landzberg MJ, Gatzoulis MA, Lucron H, Lambert J, Marçon F, Alexander ME, Walsh EP. Value of programmed ventricular stimulation after tetralogy of fallot repair: a multicenter study. Circulation. 2004;109:1994–2000.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Grieco D, Peichl P, Cihák R, Kautzner J. Successful ablation of ventricular tachycardia after correction of tetralogy of Fallot. Herzschrittmachertherapie Elektrophysiologie. 2014;25:116–20.CrossRefPubMedGoogle Scholar
  45. 45.
    Laredo M, Frank R, Waintraub X, Gandjbakhch E, Iserin L, Hascoët S, Himbert C, Gallais Y, Hidden-Lucet F, Duthoit G. Ten-year outcomes of monomorphic ventricular tachycardia catheter ablation in repaired tetralogy of Fallot. Arch Cardiovasc Dis. 2017;110:292–302.CrossRefPubMedGoogle Scholar
  46. 46.
    Moore JP, Mondésert B, Lloyd MS, Cook SC, Zaidi AN, Pass RH, John AS, Fish FA, Shannon KM, Aboulhosn JA, Khairy P, Alliance for Adult Research in Congenital Cardiology (AARCC). Clinical experience with the subcutaneous implantable cardioverter-defibrillator in adults with congenital heart disease. Circulation: Arrhythmia and Electrophysiology. 2016;9(9). pii:e004338.Google Scholar
  47. 47.
    Attenhofer Jost CH, Connolly HM, Dearani JA, Edwards WD, Danielson GK. Ebstein’s anomaly. Circulation. 2007;115:277–85.CrossRefPubMedGoogle Scholar
  48. 48.
    Freeman A, Byard RW. Ebstein anomaly and sudden childhood death. J Forensic Sci. 2017 Sep 20. doi: 10.1111/1556–4029.13652.Google Scholar
  49. 49.
    Sherwin ED, Abrams DJ. Ebstein anomaly. Card Electrophysiol Clin. 2017;9:245–54.CrossRefPubMedGoogle Scholar
  50. 50.
    Huang CJ, Chiu IS, Lin FY, Chen WJ, Lin JL, Lo HM, Wu MH, Chu SH. Role of electrophysiological studies and arrhythmia intervention in repairing Ebstein’s anomaly. Thorac Cardiovasc Surg. 2000;48:347–50.CrossRefPubMedGoogle Scholar
  51. 51.
    Chauvaud SM, Brancaccio G, Carpentier AF. Cardiac arrhythmia in patients undergoing surgical repair of Ebstein’s anomaly. Ann Thorac Surg. 2001;71:1547–52.CrossRefPubMedGoogle Scholar
  52. 52.
    Dallaglio PD, Anguera I, Jiménez-Candil J, et al. Impact of previous cardiac surgery on long-term outcome of cavotricuspid isthmus-dependent atrial flutter ablation. Europace. 2016;18:873–80.CrossRefPubMedGoogle Scholar
  53. 53.
    Scaglione M, Caponi D, Ebrille E, Di Donna P, Di Clemente F, Battaglia A, Raimondo C, Appendino M, Gaita F. Very long-term results of electroanatomic-guided radiofrequency ablation of atrial arrhythmias in patients with surgically corrected atrial septal defect. Europace. 2014;16:1800–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Katritsis DG, Wellens HJ, Josephson ME. Mahaim accessory pathways. Arrhythmia Electrophysiol Rev. 2017;6:29–32.CrossRefGoogle Scholar
  55. 55.
    Gul I, Roziman Q, Khan AH. Mahaim tachycardia induced cardiomyopathy. J Coll Physicians Surg Pak. 2016;26:S80–2.PubMedGoogle Scholar
  56. 56.
    Asakai H, Fenwick L, Hamilton RM. Electroanatomical voltage mapping of atrial Mahaim potentials to guide catheter ablation. Hear Case Rep. 2016;2:499–501.Google Scholar
  57. 57.
    Tseng ZH, Scheinman M. Persistent long R-P tachycardia. Card Electrophysiol Clin. 2010;2:225–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Ho RT. Diagnosis and ablation of long RP supraventricular tachycardias. Curr Treat Options Cardiovasc Med. 2015;17:370.CrossRefPubMedGoogle Scholar
  59. 59.
    Vollmann D, Hansen C. Permanent junctional reciprocating tachycardia causing cardiomyopathy in an adult woman. Herzschrittmachertherapie Elektrophysiologie. 2016;27:404–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Brooks R, Burgess JH. Idiopathic ventricular tachycardia. A review. Medicine (Baltimore). 1988;67:271–94.CrossRefGoogle Scholar
  61. 61.
    Globits S, Kreiner G, Frank H, Heinz G, Klaar U, Frey B, Gössinger H. Significance of morphological abnormalities detected by MRI in patients undergoing successful ablation of right ventricular outflow tract tachycardia. Circulation. 1997;96:2633–40.CrossRefPubMedGoogle Scholar
  62. 62.
    Eguchi M, Tsuchihashi K, Nakata T, Hashimoto A, Shimamoto K. Right ventricular abnormalities assessed by myocardial single-photon emission computed tomography using technetium-99m sestamibi/tetrofosmin in right ventricle-originated ventricular tachyarrhythmias. J Am Coll Cardiol. 2000;36:1767–73.CrossRefPubMedGoogle Scholar
  63. 63.
    Yarlagadda RK, Iwai S, Stein KM, Markowitz SM, Shah BK, Cheung JW, Tan V, Lerman BB, Mittal S. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation. 2005;112:1092–7.CrossRefPubMedGoogle Scholar
  64. 64.
    Rodriguez LM, Smeets JL, Timmermans C, Wellens HJ. Predictors for successful ablation of right- and left-sided idiopathic ventricular tachycardia. Am J Cardiol. 1997;79:309–14.CrossRefPubMedGoogle Scholar
  65. 65.
    Lamba J, Redfearn DP, Michael KA, Simpson CS, Abdollah H, Baranchuk A. Radiofrequency catheter ablation for the treatment of idiopathic premature ventricular contractions originating from the right ventricular outflow tract: a systematic review and meta-analysis. Pacing Clin Electrophysiol PACE. 2014;37:73–8.CrossRefPubMedGoogle Scholar
  66. 66.
    Tongers J, Schwerdtfeger B, Klein G, Kempf T, Schaefer A, Knapp J-M, Niehaus M, Korte T, Hoeper MM. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J. 2007;153:127–32.CrossRefPubMedGoogle Scholar
  67. 67.
    Tateno S, Niwa K, Nakazawa M, Iwamoto M, Yokota M, Nagashima M, Echigo S, Kado H, Shima M, Gatzoulis MA. Risk factors for arrhythmia and late death in patients with right ventricle to pulmonary artery conduit repair–Japanese multicenter study. Int J Cardiol. 2006;106:373–81.CrossRefPubMedGoogle Scholar
  68. 68.
    McLaughlin VV. Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur Respir Rev Off J Eur Respir Soc. 2011;20:262–9.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Stefan Bogdan
    • 1
    • 2
  • Radu Vătăşescu
    • 1
    • 2
  • Maria Dorobanţu
    • 1
    • 3
  1. 1.“Carol Davila” University of Medicine and PharmacyBucharestRomania
  2. 2.Cardiology DepartmentClinical Electrophysiology and Cardiac Pacing Laboratory, Clinical Emergency HospitalBucharestRomania
  3. 3.Cardiology DepartmentClinical Emergency HospitalBucharestRomania

Personalised recommendations